Royalty Pharma plc Payments to Acquire Equity Method Investments
Royalty Pharma plc (RPRX) reported Payments to Acquire Equity Method Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2026-02-11
- Royalty Pharma plc payments to acquire equity method investments for the quarter ending 2025-12-31 was $0.00.
- Royalty Pharma plc payments to acquire equity method investments for the quarter ending 2025-09-30 was $0.00.
- Royalty Pharma plc payments to acquire equity method investments for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc payments to acquire equity method investments for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Royalty Pharma plc payments to acquire equity method investments for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Royalty Pharma plc payments to acquire equity method investments for fiscal 2024 was $10.96M, a 12.65% decline from fiscal 2023.
- Royalty Pharma plc payments to acquire equity method investments for fiscal 2023 was $12.54M, a 26.74% increase from fiscal 2022.
- Royalty Pharma plc payments to acquire equity method investments for fiscal 2022 was $9.90M, a 71.61% decline from fiscal 2021.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 10-K · filed 2026-02-11 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $0.00 derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-11 | $3.98M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $0.00 derived: sum of 2 quarters · filed 2026-02-11 | $3.98M derived: sum of 3 quarters · filed 2026-02-11 | $10.96M 10-K · filed 2026-02-11 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.98M derived: sum of 2 quarters · filed 2025-11-05 | $10.96M 10-Q · filed 2025-11-05 | $12.95M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $10.96M 10-Q · filed 2025-08-06 | $12.95M derived: sum of 3 quarters · filed 2026-02-11 | $16.93M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $6.97M 10-Q · filed 2025-05-08 | $8.96M derived: sum of 2 quarters · filed 2026-02-11 | $12.95M derived: sum of 3 quarters · filed 2026-02-11 | $15.93M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $5.98M derived: sum of 2 quarters · filed 2026-02-11 | $8.96M derived: sum of 3 quarters · filed 2026-02-11 | $12.54M 10-K · filed 2026-02-11 |
| 2023-09-30 | $3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $6.97M derived: sum of 2 quarters · filed 2024-11-06 | $10.55M 10-Q · filed 2024-11-06 | $10.55M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.57M 10-Q · filed 2024-08-08 | $6.57M derived: sum of 3 quarters · filed 2025-02-12 | $13.41M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $3.58M 10-Q · filed 2024-05-09 | $3.58M derived: sum of 2 quarters · filed 2025-02-12 | $10.43M derived: sum of 3 quarters · filed 2025-02-12 | $10.43M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $6.85M derived: sum of 2 quarters · filed 2025-02-12 | $6.85M derived: sum of 3 quarters · filed 2025-02-12 | $9.90M 10-K · filed 2025-02-12 |
| 2022-09-30 | $6.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $6.85M derived: sum of 2 quarters · filed 2023-11-08 | $9.90M 10-Q · filed 2023-11-08 | $16.43M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.05M 10-Q · filed 2023-08-08 | $9.59M derived: sum of 3 quarters · filed 2024-02-15 | $20.48M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $3.05M 10-Q · filed 2023-05-09 | $9.59M derived: sum of 2 quarters · filed 2024-02-15 | $20.48M derived: sum of 3 quarters · filed 2024-02-15 | $29.19M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $17.43M derived: sum of 2 quarters · filed 2024-02-15 | $26.14M derived: sum of 3 quarters · filed 2024-02-15 | $34.85M 10-K · filed 2024-02-15 |
| 2021-09-30 | $10.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $19.61M derived: sum of 2 quarters · filed 2022-11-08 | $28.32M 10-Q · filed 2022-11-08 | $39.21M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $8.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $17.43M 10-Q · filed 2022-08-04 | $28.32M derived: sum of 3 quarters · filed 2023-02-15 | $28.32M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $8.71M 10-Q · filed 2022-05-05 | $19.61M derived: sum of 2 quarters · filed 2023-02-15 | $19.61M derived: sum of 3 quarters · filed 2023-02-15 | $35.73M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $10.89M derived: sum of 2 quarters · filed 2023-02-15 | $27.01M derived: sum of 3 quarters · filed 2023-02-15 | $40.16M 10-K · filed 2023-02-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $16.12M derived: sum of 2 quarters · filed 2021-11-10 | $29.26M 10-Q · filed 2021-11-10 | $33.62M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $16.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $29.26M 10-Q · filed 2021-08-11 | $33.62M derived: sum of 3 quarters · filed 2022-02-15 | $37.62M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $13.14M 10-Q · filed 2021-05-11 | $17.50M derived: sum of 2 quarters · filed 2022-02-15 | $21.50M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $8.36M derived: sum of 2 quarters · filed 2022-02-15 | $27.04M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $22.68M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $18.68M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $24.17M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |